All In Biotech

Drug Trial Radar · NCT05547100

Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan

A Phase 1, Open-Label Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan in Healthy Lactating Women

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Sep 14, 2022

Primary completion

Nov 19, 2022

Study completion Nov 19, 2022

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical lactation study is to provide information regarding the PK and amount of OLZ/SAM in breast milk and estimated infant exposure.

Conditions

  • Focus of Study is on Healthy Lactating Women

Interventions

  • LYBALVIDrug

    5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve from time zero to 48 hours post-dose (AUC0 48)Time frame: Up to 15 days
  2. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)Time frame: Up to 15 days
  3. Area under the concentration-time curve from time zero to infinity (AUC∞)Time frame: Up to 15 days
  4. \Maximum observed concentration (Cmax)Time frame: Up to 15 days
  5. Time to reach Cmax (tmax)Time frame: Up to 15 days
  6. Terminal half-life (t½)Time frame: Up to 15 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigator Site

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.